Medtronic received information that approximately three years, four months post-implant of this transcatheter pulmonary bioprosthetic valve implanted in another manufacturer's valve, the patient presented with progressive exertional dyspnea, chest pain, right ventricular outflow tract (rvot) obstruction, right ventricle (rv) dilation, rv systolic dysfunction, and an echogenic mass within the valve.Also present were symptoms of endocarditis and anemia.The patient was treated with antibiotics, and a stent was placed within the infected right ventricle-pulmonary artery (rv-pa) conduit to ameliorate the rvot obstruction.The angiogram revealed this valve was not changed from its initial appearance post-implantation.No adverse patient effects were reported.There is no allegation that the valve caused or contributed to the endocarditis.However, in the physician's opinion the valve did cause or contribute to the rvot obstruction.
|
Product analysis: the device remains implanted, therefore, no product analysis can be performed.Conclusion: the device history record was reviewed and showed that this product met all manufacturing specifications for product released for distribution.No issues were identified that would have impacted this event.A review of the sterility lot record confirms that the biological indicators (bi) tested negative for both tissue and solution.No conclusion can be made to the reported clinical observations at this time.Medtronic will continue to monitor for future similar events.(b)(4).
|